Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 27 Sept, 17:54 UTC

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum…

science

Sources

• T2Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth DisorderFierce Biotech / Fierce Healthcare / MedCity / GEN27 Sept, 17:54